San Diego-based Acadia Pharmaceuticals Inc. reported a net loss of $40.4 million in the first quarter of 2015, more than double the net loss of $17.8 million during the same quarter last year.

The net loss for the first quarter of 2015 included $14.5 million in noncash, stock-based compensation expense, and $9 million of noncash, stock-based compensation in connection with the retirement of Acadia’s former CEO, Uli Hacksell.

Acadia (Nasdaq: ACAD) focuses on the development and commercialization of medicines that address unmet medical needs in neurological and related central nervous system disorders.